Printer Friendly

CAMBRIDGE BIOTECH WITHDRAWS SHELF REGISTRATION

 WORCESTER, Mass., Feb. 16 /PRNewswire/ -- Cambridge Biotech Corporation (NASDAQ: CBCX) announced today that it is seeking withdrawal of its recent $100 million shelf registration statement with the Securities and Exchange Commission. The registration statement was filed on Dec. 3, 1992.
 Peter Hartman, Cambridge Biotech vice president-finance and chief financial officer, commented: "The shelf registration led people to believe that a large public offering was contemplated in the near term. This was never the company's intention. Our intent was to utilize revised SEC shelf registration rules in order to be ready for possible offerings over the next two years. For avoidance of doubt, withdrawing this registration is in the company's best interest."
 Cambridge Biotech Corporation is a leading diagnostics and vaccine company involved in infectious diseases. The company is developing vaccines, adjuvants, and diagnostics for humans and animals.
 -0- 2/16/93
 /CONTACT: Peter P. Hartman, vice president-finance and chief financial officer of Cambridge Biotech Corp., (508) 797-5777/
 (CBCX)


CO: Cambridge Biotech Corporation ST: Massachusetts IN: MTC SU:

CH -- NE002 -- 6712 02/16/93 08:42 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 16, 1993
Words:176
Previous Article:UNITED HEALTHCARE REPORTS RECORD YEAR-END RESULTS; BOARD DECLARES DIVIDEND, ELECTS NEW DIRECTOR
Next Article:NATURAL GAS COGENERATION IS RELIABLE, STUDY CONCLUDES
Topics:


Related Articles
CAMBRIDGE BIOTECH AND GULL LABORATORIES ENTER MANUFACTURING/DISTRIBUTION AGREEMENT
CAMBRIDGE BIOTECH CORPORATION REPORTS SECOND QUARTER 1992 RESULTS
CAMBRIDGE BIOTECH CORPORATION ACQUIRES RIGHTS TO DYNAGEN'S RAPID ANTIBODY TESTS FOR TUBERCULOSIS AND MYCOBACTERIA
CAMBRIDGE BIOTECH AND DYNAGEN SIGN AGREEMENT FOR WORLDWIDE DISTRIBUTION OF DYNAGEN'S NEW TUBERCULOSIS TESTS
CAMBRIDGE BIOTECH REPORTS FIRST QUARTER 1993 RESULTS
CAMBRIDGE BIOTECH CORPORATION ANNOUNCES NEW VICE PRESIDENT OF MEDICAL AFFAIRS
CAMBRIDGE BIOTECH CORPORATION THIRD QUARTER RESULTS
CAMBRIDGE BIOTECH CORPORATION DISPUTES ALLEGATIONS IN COMPLAINT
Cambridge Biotech Corporation Reports on District Court Hearing

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters